Calithera Biosciences Inc. (South San Francisco, CA, USA) is developing CB-839, a leading candidate from a program of glutaminase inhibitors, for the potential oral treatment of multiple cancers, including AML. This evidence concerns the gene GLS and acute myeloid leukemia.